Key Takeaways Black Diamond completed enrollment in a mid-stage silevertinib study in frontline NSCLC.BDTX will share response data from 43 NSCLC patients in the fourth quarter of 2025.The company seeks partners to advance silevertinib as its sole pipeline program.Black Diamond Therapeutics, Inc.’s (BDTX) lead pipeline candidate, silevertinib, is a brain penetrant, fourth-generation epidermal growth factor receptor (“EGFR”) MasterKey inhibitor targeting epidermal growth factor receptor mutant (EGFRm) non-sm ...